Scarica l'app Stockscreener
2.53
4.12%
0.10
Dopo l'orario di chiusura:
2.53
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.43
Aprire:
$2.43
Volume 24 ore:
7.61M
Relative Volume:
1.66
Capitalizzazione di mercato:
$510.11M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-1.1934
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
+14.48%
1M Prestazione:
+69.80%
6M Prestazione:
+42.94%
1 anno Prestazione:
+39.01%
Intervallo 1D:
$2.395
$2.58
Intervallo di 1 settimana:
$2.09
$2.58
Portata 52W:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Confronta ESPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.53 | 467.76M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
153.20 | 67.75B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.29 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.84 | 43.70B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.48 | 21.51B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
380.47 | 18.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Is this a good reentry point in Esperion Therapeutics Inc.Market Activity Recap & Proven Capital Preservation Tips - Newser
Market reaction to Esperion Therapeutics Inc.’s recent newsShare Buyback & AI Enhanced Market Trend Forecasts - Newser
Combining machine learning predictions for Esperion Therapeutics Inc.July 2025 Outlook & Daily Volume Surge Signals - Newser
Esperion Therapeutics Inc. stock chart pattern explained2025 Bull vs Bear & High Return Trade Opportunity Guides - Newser
Real time pattern detection on Esperion Therapeutics Inc. stockPortfolio Value Summary & Growth Focused Stock Pick Reports - Newser
Will Esperion Therapeutics Inc. benefit from macro trendsJuly 2025 Institutional & Intraday High Probability Alerts - Newser
Tools to monitor Esperion Therapeutics Inc. recovery probabilityJuly 2025 Reactions & Fast Exit/Entry Strategy Plans - Newser
Published on: 2025-09-03 04:01:00 - Newser
Technical analysis overview for Esperion Therapeutics Inc. stockWeekly Trade Summary & Weekly High Return Forecasts - Newser
Candlestick signals on Esperion Therapeutics Inc. stock todayWeekly Trend Summary & AI Forecasted Stock Moves - Newser
What institutional flow reveals about Esperion Therapeutics Inc.Wall Street Watch & Safe Swing Trade Setups - Newser
Is Esperion Therapeutics Inc. benefiting from innovation trendsQuarterly Profit Review & AI Powered Buy/Sell Recommendations - khodrobank.com
Using flow based indicators on Esperion Therapeutics Inc.2025 Momentum Check & Expert Curated Trade Ideas - Newser
Using Bollinger Bands to evaluate Esperion Therapeutics Inc.Quarterly Risk Review & Safe Capital Growth Stock Tips - Newser
Published on: 2025-09-02 13:26:49 - Newser
Is Esperion Therapeutics Inc. stock ready for a breakout2025 EndofYear Setup & Accurate Entry and Exit Point Alerts - Newser
Can Esperion Therapeutics Inc. keep up with sector leadersOil Prices & Weekly Setup with High ROI Potential - khodrobank.com
Movement Recap: Can Esperion Therapeutics Inc. scale operations efficientlyGap Down & Real-Time Chart Pattern Alerts - khodrobank.com
Esperion rises after revenue beat, Q1 profitability expectation - MSN
Using data tools to time your Esperion Therapeutics Inc. exit2025 Institutional Moves & Accurate Trade Setup Notifications - Newser
Published on: 2025-09-01 19:45:56 - Newser
Is Esperion Therapeutics Inc. forming a bullish divergenceJuly 2025 Institutional & Pattern Based Trade Signal System - khodrobank.com
Should you hold or exit Esperion Therapeutics Inc. nowJuly 2025 Reactions & Free Growth Oriented Trading Recommendations - Newser
Analyzing Esperion Therapeutics Inc. with risk reward ratio chartsProduct Launch & Fast Entry Momentum Alerts - Newser
Published on: 2025-09-01 01:32:54 - Newser
Chart based analysis of Esperion Therapeutics Inc. trendsIndex Update & Fast Momentum Entry Tips - Newser
Using data models to predict Esperion Therapeutics Inc. stock movement2025 Valuation Update & AI Powered Market Trend Analysis - Newser
Heatmap analysis for Esperion Therapeutics Inc. and competitorsEarnings Overview Report & Safe Investment Capital Preservation Plans - Newser
Signal strength of Esperion Therapeutics Inc. stock in tech scannersMarket Growth Report & Fast Momentum Entry Tips - Newser
Will a bounce in Esperion Therapeutics Inc. offer an exitWeekly Loss Report & Risk Adjusted Swing Trade Ideas - Newser
Understanding Esperion Therapeutics Inc.’s price movementJuly 2025 Decliners & Momentum Based Trading Signals - Newser
Reversal indicators forming on Esperion Therapeutics Inc. stockMarket Sentiment Review & Growth Focused Investment Plans - Newser
Esperion Therapeutics Inc. stock trendline breakdownWeekly Trend Recap & Smart Money Movement Tracker - Newser
Analyzing recovery setups for Esperion Therapeutics Inc. investorsOil Prices & Growth Focused Stock Reports - Newser
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Esperion Therapeutics Inc Azioni (ESPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Halladay Benjamin | Chief Financial Officer |
Jul 17 '25 |
Sale |
1.11 |
11 |
12 |
474,462 |
3.60%
0.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):